ClinicalTrials.gg
CompletedNCT04973553Updated May 29, 2024

Dose Escalation Upper Limb Rehabilitation in Stroke

An interventional study of upper limb rehabilitation in Stroke, sponsored by Hasselt University. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Hasselt University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A phase 1, single-ascending dose clinical trial will be conducted. This study will be designed to test increasing doses of multimodal exercise in successive cohorts of six participants (cumulative 3 + 3 design)[22] (Figure 1).

Maximum dose is reached when two or more participants experience DLT. DLT, dose-limiting tolerance.

The 'dose' will be defined as the ability to reach a fixed maximal level of exercise (type, duration (including session length) in the first two weeks post-stroke without experiencing dose-limiting tolerance (DLT). DLT thresholds will be based on failure to completeshould be less than 80% of prescribed 3-day rehabilitation dose due to pain, rate of perceived exertion, fatigue, or effort required.

Rehabilitation and measurement sessions will be held at either at the Stroke or Geriatric Units at Campus Sint-Jan, Genk or at the rehabilitation unit at Sint-Barbara, Lanaken and Cliniques Saint-Luc with medical services on site. All participants will be monitored for fatigue and pain pre, during and at post-intervention daily. The researchers (PI of project [Dr Peter Hallet, ZOL] Postdoctoral Researcher [Dr Lisa Tedesco Triccas, UHasselt] and PhD/Masters Students [UHasselt) will conduct the clinical tests and will conduct the rehabilitation program.

02

Conditions studied

  • Stroke

Browse trials for

03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's enrollment of 18 is below the median of 50 across 5,482 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Hasselt University is the lead sponsor of 203 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation,
  2. been admitted to the acute hospital for rehabilitation,
  3. UL hemiparesis or hemiplegia with a ≥ trace of muscle contraction (≥grade 1 at wrist extensors measured by the MRC Scale and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS),
  4. the age of > 18 years and (e) the ability to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  1. other neurological impairments that could interfere with the protocol such as multiple sclerosis and Parkinson's
  2. serious communication, cognitive and language deficits which might hamper the assessment (score of >1 on the command item of the NIHSS).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    participants with acute stroke

    (a) a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation, (b) been admitted to the acute hospital for rehabilitation, (c) Upper limb hemiparesis or hemiplegia with a trace of muscle contraction:≥grade 1 at shoulder (abductors or elevators) or wrist/finger extensors measured by the MRC Scale and a score of \<61 on the Motricity Index and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS)\[24\], (d) the age of \> 18 years and (e) the ability to provide informed consent.

    Other: upper limb rehabilitation

Interventions

  • Otherupper limb rehabilitation

    the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment of Motor Recovery after Stroke

    a stroke-specific, performance-based impairment index.The scale is comprised of five domains and there are 155 items in total (motor functioning, sensory functioning, balance, joint range motion, joint pain). Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.

    Time frame: baseline

  2. Fugl-Meyer Assessment of Motor Recovery after Stroke

    a stroke-specific, performance-based impairment index.The scale is comprised of five domains and there are 155 items in total (motor functioning, sensory functioning, balance, joint range motion, joint pain). Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.

    Time frame: day 6

  3. Fugl-Meyer Assessment of Motor Recovery after Stroke

    a stroke-specific, performance-based impairment index.The scale is comprised of five domains and there are 155 items in total (motor functioning, sensory functioning, balance, joint range motion, joint pain). Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.

    Time frame: day 9

  4. Fugl-Meyer Assessment of Motor Recovery after Stroke

    a stroke-specific, performance-based impairment index.The scale is comprised of five domains and there are 155 items in total (motor functioning, sensory functioning, balance, joint range motion, joint pain). Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.

    Time frame: day 12

  5. Fugl-Meyer Assessment of Motor Recovery after Stroke

    a stroke-specific, performance-based impairment index.The scale is comprised of five domains and there are 155 items in total (motor functioning, sensory functioning, balance, joint range motion, joint pain). Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.

    Time frame: day 15

Secondary outcomes

  1. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 3

  2. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 4

  3. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 5

  4. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 6

  5. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 7

  6. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 8

  7. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 9

  8. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 10

  9. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 11

  10. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 12

  11. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 13

  12. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 14

  13. Motricity index

    Measurement of upper limb strength. The weighted score based on the ordinal 6 point scale of Medical Research Council was used to measure maximal isometric muscle strength.

    Time frame: day 15

  14. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 3

  15. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 4

  16. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 5

  17. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 6

  18. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 7

  19. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 8

  20. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 9

  21. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 10

  22. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 11

  23. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 12

  24. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 13

  25. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 14

  26. Visual Analog Scale of Fatigue (VAS-f)

    The scale consists of 18 items relating to the subjective experience of fatigue.Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).

    Time frame: day 15

  27. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 3

  28. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 4

  29. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 5

  30. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 6

  31. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 7

  32. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 8

  33. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 9

  34. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 10

  35. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 11

  36. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 12

  37. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 13

  38. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 14

  39. Borg RPE Scale

    Measurement of physical activity intensity (6 to 20 scale)

    Time frame: day 15

  40. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 3

  41. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 4

  42. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 5

  43. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 6

  44. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 7

  45. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 8

  46. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 9

  47. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 10

  48. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 11

  49. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 12

  50. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 13

  51. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 14

  52. Numeric rating scale pain

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: day 15

07

Study locations

1 site
  • Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
08

References and documents

Publications

  • Triccas LT, Hallet P, Cardeynaels S, Ward N, Bertels N, Thijs L, Lejeune T, Lamers I, Spooren A, Feys P. Higher Doses of Intensive Upper Limb Rehabilitation for Moderate to Severe Impairment in Acute, Subacute Stroke: Phase I Dose Escalation Study. Neurorehabil Neural Repair. 2025 Sep;39(9):752-764. doi: 10.1177/15459683251338797. Epub 2025 Jun 28. PubMed 40579997 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in May 2024, 33 months.

Of 2,859 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 33 months is above that.

Counting every sponsor, half of 2,988 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2021
First posted
Jul 22, 2021
StartActual
Aug 20, 2021
Primary completionActual
May 27, 2024
CompletionActual
May 27, 2024
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04973553
Lead sponsor
Hasselt University
Collaborators
Ziekenhuis Oost-Limburg
Responsible party
Peter Feys (Principal Investigator, Hasselt University) — Principal investigator
First posted
Jul 22, 2021
Start date
Aug 20, 2021
Primary completion
May 27, 2024
Completion
May 27, 2024
Last update
May 29, 2024

Study contacts

Peter Feys, prof. dr.
principal investigator · Hasselt University
Lisa Tabone, dr.
study chair · Hasselt University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion